181 related articles for article (PubMed ID: 32231231)
21. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus.
Baertsch MA; Leber MF; Bossow S; Singh M; Engeland CE; Albert J; Grossardt C; Jäger D; von Kalle C; Ungerechts G
Cancer Gene Ther; 2014 Sep; 21(9):373-80. PubMed ID: 25145311
[TBL] [Abstract][Full Text] [Related]
22. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.
Iankov ID; Allen C; Federspiel MJ; Myers RM; Peng KW; Ingle JN; Russell SJ; Galanis E
Mol Ther; 2012 Jun; 20(6):1139-47. PubMed ID: 22334023
[TBL] [Abstract][Full Text] [Related]
23. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
24. Forskolin Enhances Antitumor Effect of Oncolytic Measles Virus by Promoting Rab27a Dependent Vesicular Transport System.
Xia M; Wang Y; Xia Y; Zeng J
Curr Microbiol; 2024 Feb; 81(4):93. PubMed ID: 38334775
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.
Li H; Peng KW; Russell SJ
Hum Gene Ther; 2012 Mar; 23(3):295-301. PubMed ID: 22235810
[TBL] [Abstract][Full Text] [Related]
26. Measles virus for cancer therapy.
Russell SJ; Peng KW
Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112
[TBL] [Abstract][Full Text] [Related]
27. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.
Ayala-Breton C; Suksanpaisan L; Mader EK; Russell SJ; Peng KW
Mol Ther; 2013 Oct; 21(10):1930-7. PubMed ID: 23842448
[TBL] [Abstract][Full Text] [Related]
28. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E
Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881
[TBL] [Abstract][Full Text] [Related]
29. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
Engeland CE; Grossardt C; Veinalde R; Bossow S; Lutz D; Kaufmann JK; Shevchenko I; Umansky V; Nettelbeck DM; Weichert W; Jäger D; von Kalle C; Ungerechts G
Mol Ther; 2014 Nov; 22(11):1949-59. PubMed ID: 25156126
[TBL] [Abstract][Full Text] [Related]
30. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo.
Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY
J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554
[TBL] [Abstract][Full Text] [Related]
31. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
[TBL] [Abstract][Full Text] [Related]
33. Small molecules baicalein and cinnamaldehyde are potentiators of measles virus-induced breast cancer oncolysis.
Kuo YT; Liu CH; Wong SH; Pan YC; Lin LT
Phytomedicine; 2021 Aug; 89():153611. PubMed ID: 34144429
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic potential of oncolytic measles virus: promises and challenges.
Galanis E
Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
[TBL] [Abstract][Full Text] [Related]
35. Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling.
Xia M; Gonzalez P; Li C; Meng G; Jiang A; Wang H; Gao Q; Debatin KM; Beltinger C; Wei J
J Virol; 2014 May; 88(9):5152-64. PubMed ID: 24574393
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.
Allen C; Opyrchal M; Aderca I; Schroeder MA; Sarkaria JN; Domingo E; Federspiel MJ; Galanis E
Gene Ther; 2013 Apr; 20(4):444-9. PubMed ID: 22914495
[TBL] [Abstract][Full Text] [Related]
37. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
[TBL] [Abstract][Full Text] [Related]
38. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ
PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
[TBL] [Abstract][Full Text] [Related]
40. Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus.
Ayala-Breton C; Russell LO; Russell SJ; Peng KW
J Virol; 2014 Aug; 88(15):8332-9. PubMed ID: 24829351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
